Colon epithelial and colon cancer cells

Colon epithelial cells are the specialized cells forming the luminal surface of the large intestine, responsible for water and electrolyte absorption, mucus production, and maintaining a mucosal barrier (NIH, 2023). Colon cancer cells arise from the malignant transformation of these epithelial cells, often driven by mutations in the Wnt/beta-catenin, MAPK, and PI3K signaling pathways (PubMed, PMC6356367). While these cells are the focus of colorectal cancer treatments, the term refers to a cellular population or tissue type rather than a single druggable molecular target like a receptor or enzyme. Therapeutic interventions targeting these cells include cytotoxic chemotherapies like 5-fluorouracil and targeted monoclonal antibodies like cetuximab, which binds to the Epidermal Growth Factor Receptor (EGFR) expressed on the cell surface (PubChem, 2024). Distinguishing between normal and malignant colon cells is a primary challenge in oncology to avoid severe gastrointestinal side effects. Biomarkers such as KRAS mutations and MSI status are used to guide treatment decisions for these cell populations (PubMed, PMC7073331). The transition from normal epithelium to adenocarcinoma involves a well-characterized sequence of genetic alterations known as the adenoma-carcinoma sequence (NIH, 2022). Understanding the biology of these cells is crucial for developing therapies that can selectively target the unique metabolic and signaling profiles of cancerous cells.

Other names

Colonic epitheliumColorectal cancer cellsCRC cellsIntestinal epithelial cellsColonocytes

Therapeutic agents targeting these cells function through various mechanisms, including the inhibition of thymidylate synthase to disrupt DNA synthesis, blockade of the Epidermal Growth Factor Receptor (EGFR) to halt proliferative signaling, and inhibition of Vascular Endothelial Growth Factor (VEGF) to prevent tumor angiogenesis (PubMed, PMC6356367; PubChem, 2024).